{"task_id": "906182652ac22a8a", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 216/464)", "text": "compensation of liver\nHepatocellular Carcinoma\n205\n\n--- Page 227 ---\ndisease (ascites, encephalopathy, jaundice, and var\niceal bleeding)\nMETASTATIC\nbone pain, dyspnea\nCONSTITUTIONAL\nweight loss, fever due to cen\ntral tumor necrosis\nPARANEOPLASTIC\nSYNDROME\nhypoglycemia,\nerythrocytosis, hypercalcemia, water diarrhea, cuta\nneous features\nSTAGING FOR HEPATOCELLULAR CARCINOMA OR\nINTRAHEPATIC BILE DUCT CANCER\nTNM STAGING\nT stage\n\u0002 T1=solitary tumor without vascular invasion\n\u0002 T2=solitary tumor with vascular invasion or mul\ntiple tumors \u00045 cm\n\u0002 T3=multiple tumors >5 cm or tumor that\ninvolves major branch of portal or hepatic vein\n\u0002 T4=invades adjacent structures other than gall\nbladder or with perforation of the visceral\nperitoneum\nN stage (along portal vein, hepatic artery, inferior\nvena cava, hepatoduodenal ligament)\n\u0002 N1=regional LN\nM stage\n\u0002 M1=distant metastasis\nSTAGE GROUPINGS\nStage\nTNM @=any\n5 year survival\nI\nT1N0M0\n55%\nII\nT2N0M0\n37%\nIIIA\nT3N0M0\nIIIB\nT4N0M0g\n16%\nIIIC\nT@N1M0\nIV\nT@N@M1\n<5%\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, glucose, AST, ALT,\nALP, bilirubin, INR, PTT, albumin, AFP\n\u0002\nIMAGING\nCXR, CT abd (biphasic or triphasic), U/S\nabd, MRI abd, liver/spleen scan (if suspect FNH)\nSPECIAL\n\u0002\nBIOPSY\nliver biopsy if AASLD clinical criteria\n(atypical vascular pattern on imaging + AFP\n>100 U/L) not met or if biopsy would have an\nimpact on management options\nDIAGNOSTIC ISSUES\nCT SCAN\ncharacteristic features for hemangioma,\nFNH (central scar)\nLIVER SPLEEN SCAN\nuseful for distinguishing focal\nnodular hyperplasia and hepatoma\nGALLIUM SCAN\nuseful for identifying hepatoma\nand abscesses (increased blood flow)\nAPPROACH TO HEPATOMA\nstart with U/S abd,\nfollowed by CT/nuclear scans to rule out other causes\n\u0002\nLOW CLINICAL SUSPICION\nconsider percutaneous\nbiopsy\n\u0002\nHIGH CLINICAL SUSPICION (known cirrhosis)\npatient\nshould be referred to hepatobiliary surgeon for\nresection. Biopsy is not required\nMANAGEMENT\nEARLY STAGE (1 lesion or 3 lesions <3 cm, Child\nPugh A B, and ECOG 0)\nif only 1 lesion <2 cm or\nCIS, bilirubin not significantly elevated and no portal\nhypertension, proceed to resection. For unresectable\ndisease up to 3 lesions <3 cm, consider liver trans\nplant if no comorbidity, and percutaneous ethanol\ninjection/radiofrequency\nablation\nif\nsignificant\ncomorbidities; 5 year survival 50 70%\nINTERMEDIATE\nSTAGE\n(multinodular\ndisease,\nChild Pugh A B, and ECOG 0)\nchemoembolization.\nMedian survival 6 16 months\nADVANCED STAGE (portal invasion, N1, M1, Child\nPugh A B, or ECOG 1 2)\nfor patients with Child\nPugh A disease, consider sorafenib. Chemoemboliza\ntion may also represent an option for some patients.\nMedian survival 6 16 months\nTERMINAL STAGE (Child Pugh C or ECOG >2)\nbest supportive care. Median survival <3 months\nBarcelona Clinic Treatment Algorithm\nTREATMENT ISSUES\nCRITERIA FOR RESECTABLE DISEASE\nwell com\npensated cirrhosis, single lobe involvement, no vas\ncular invasion, N0, M0\nCRITERIA FOR PERCUTANEOUS ETHANOL ABLA\nTION\n1 lesion <5 cm or 3 lesions <3 cm, accessible,\nno ascites, not coagulopathic, non resectable or\nrefuses surgery, awaiting transplantation. Radiofre\nquency ablation is not recommended for these\npatients as potential spread of cancer along the\npercutaneous track\nFOLLOW UP OF RESECTABLE DISEASE\nAFP every\n3 months for 2 years, then every 6 months. CT abd\nevery 6 months\nSPECIFIC ENTITIES\nHEMANGIOMA\nprevalence\n5%.\nMay\ngradually\nincrease in size due to vascular expansion. Usually\nasymptomatic and no treatment required\nFOCAL NODULAR HYPERPLASIA (FNH)\nprevalence\n0.5%. Hyperplasia of liver cells in response to hyper\nperfusion from an anomalous artery. Rarely exceeds\n10 cm. Usually asymptomatic\nDIAGNOSTIC ISSUES (CONT\u2019D)\nCLINICAL FEATURES (CONT\u2019D)\n206\nHepatocellular Carcinoma", "text_length": 3745, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 216/464)", "type": "chunk", "chunk_index": 215, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.543590", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.544461", "status": "complete", "chunks_added": 2}